According to statistics, KRAS mutations exist in more than 90% of pancreatic ductal adenocarcinomas (PDACs), 40% of colorectal cancers, and 35% of non-small cell lung cancers (NSCLCs) [71]. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.